<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02975739</url>
  </required_header>
  <id_info>
    <org_study_id>NL54535.041.15</org_study_id>
    <nct_id>NCT02975739</nct_id>
  </id_info>
  <brief_title>Feasibility of Holmium-166 Micro Brachytherapy in Head and Neck Tumors</brief_title>
  <acronym>HIT</acronym>
  <official_title>Feasibility of Holmium-166 Microspheres for Selective Intra-tumoural Treatment in Head and Neck Cancer: Biodistribution and Safety in Patients With Malignancy of the Tongue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to establish the feasibility of 166-Holmium microspheres for
      intratumoral injections in oral squamous cell carcinoma (OSCC) of the tongue.

      Participants will receive intratumoral injections with a low radioactive 166-Holmium
      microspheres followed by surgical resection
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      166-Holmium microspheres poly lactic acid microspheres are currently used in selective
      internal radiation therapy. These microspheres emits beta radiation. The majority of the
      radiation dose will be absorbed within 3.2 mm with a maximum penetration in tissue of 9 mm.
      Therefore this can result in a high local tumor ablative dose with minimal dose to healthy
      adjacent tissue.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total amount of activity leakage (in percentage) in the oral cavity rinsing fluid.</measure>
    <time_frame>upto 5 minutes after administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of (serious) adverse events</measure>
    <time_frame>Between administration and resection of the tumor (max 12 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The biodistribution of Holmium-166 microspheres after intra-tumoural injection</measure>
    <time_frame>upto 30 minutes after administration</time_frame>
    <description>SPECT Thorax and Abdomen Radioactivity in a blood and urine sample</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The biodistribution of Holmium-166 microspheres after intra-tumoural injection</measure>
    <time_frame>1-2 hours after administration</time_frame>
    <description>MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The biodistribution of Holmium-166 microspheres after intra-tumoural injection</measure>
    <time_frame>3 hours after administration</time_frame>
    <description>Radioactivity in blood and urine sample</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Radioisotopes</condition>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>Holmium-166 microspheres</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single session of 4 intratumoral injections consisting of 0.1-0.3 ml radioactive Holmium-166 microsphere suspension with a total activity 30 Megabecquerel, 7-12 days prior to surgical resection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Holmium-166 (poly L lactic acid) microspheres</intervention_name>
    <description>Intratumoral injections of Holmium-166 (poly L lactic acid) microspheres</description>
    <arm_group_label>Holmium-166 microspheres</arm_group_label>
    <other_name>Holmium microspheres</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have given written informed consent.

          2. Aged 18 years and over.

          3. Confirmed histological diagnosis of squamous cell carcinoma of the tongue.

          4. primary tumor, regional nodes, metastasis (TNM) stage T1-2 Nx M0.

          5. Eligible for local surgery with curative intent.

          6. World Health Organization (WHO) Performance status 0-2.

        Exclusion Criteria:

          1. Previous oncologic surgery and/or external beam radiation therapy on the tongue and
             oral floor.

          2. Major surgery (Oro-facial) within the past 4 weeks or incompletely healed surgical
             incisions before starting study therapy.

          3. Any unresolved toxicity greater than National Cancer Institute (NCI), Common
             Terminology Criteria for Adverse Events (CTCAE version 4.03) grade 2 from previous
             anti-cancer therapy.

          4. Pregnancy or nursing (women of child-bearing potential).

          5. Patients suffering from psychic disorders that make a comprehensive judgment
             impossible, such as psychosis, hallucinations and/or depression.

          6. Previous enrolment in the present study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marnix G Lam, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robbert C Bakker, MD, MsC</last_name>
      <email>r.c.bakker@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Marnix G Lam, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>van Es RJ, Nijsen JF, van het Schip AD, Dullens HF, Slootweg PJ, Koole R. Intra-arterial embolization of head-and-neck cancer with radioactive holmium-166 poly(L-lactic acid) microspheres: an experimental study in rabbits. Int J Oral Maxillofac Surg. 2001 Oct;30(5):407-13.</citation>
    <PMID>11720043</PMID>
  </reference>
  <reference>
    <citation>Bult W, Vente MA, Vandermeulen E, Gielen I, Seevinck PR, Saunders J, van Het Schip AD, Bakker CJ, Krijger GC, Peremans K, Nijsen JF. Microbrachytherapy using holmium-166 acetylacetonate microspheres: a pilot study in a spontaneous cancer animal model. Brachytherapy. 2013 Mar-Apr;12(2):171-7. doi: 10.1016/j.brachy.2012.08.001. Epub 2012 Sep 19.</citation>
    <PMID>22999975</PMID>
  </reference>
  <reference>
    <citation>Smits ML, Nijsen JF, van den Bosch MA, Lam MG, Vente MA, Mali WP, van Het Schip AD, Zonnenberg BA. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol. 2012 Oct;13(10):1025-34. doi: 10.1016/S1470-2045(12)70334-0. Epub 2012 Aug 22. Erratum in: Lancet Oncol. 2012 Nov;13(11):e464.</citation>
    <PMID>22920685</PMID>
  </reference>
  <reference>
    <citation>Bult W, de Leeuw H, Steinebach OM, van der Bom MJ, Wolterbeek HT, Heeren RM, Bakker CJ, van Het Schip AD, Hennink WE, Nijsen JF. Radioactive holmium acetylacetonate microspheres for interstitial microbrachytherapy: an in vitro and in vivo stability study. Pharm Res. 2012 Mar;29(3):827-36. doi: 10.1007/s11095-011-0610-7. Epub 2011 Nov 9.</citation>
    <PMID>22068276</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2016</study_first_submitted>
  <study_first_submitted_qc>November 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2016</study_first_posted>
  <last_update_submitted>November 23, 2016</last_update_submitted>
  <last_update_submitted_qc>November 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Marnix Lam</investigator_full_name>
    <investigator_title>Professor Nuclear medicine</investigator_title>
  </responsible_party>
  <keyword>Intratumoral</keyword>
  <keyword>Tongue</keyword>
  <keyword>Microspheres</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

